Beyond the Numbers: Frailty as a Therapeutic Target in CKD Authors: Rajesh Raj Published: 2026 See Clinical Research on Article 106595 Care for patients with kidney disease has historically organized itself around numbers— acid-base, electrolytes, clearances, albumin-creatinine ratios, and estimated glomerular filtration rate trajectories. A patient phenotype such as frailty sits uncomfortably in a world of numbers; it is multidimensional, reflects cumulative damage rather than a point in time, and is subjective in its early stages (e.g., self-reported exhaustion). Yet, despite its prognostic significance, frailty in chronic kidney disease (CKD) has rarely been considered a serious therapeutic target.1 In this journal, the article by Chang et al.2 describes a randomized trial in which an individualized, multicomponent program reduced frailty in nearly one-third of 242 older adults with nondialysis CKD—a 4-fold increase in frailty reversion over routine care. The findings challenge the deeper assumption that frailty is largely irreversible. The researchers enrolled frail older adults (mean age 80 years) with stage 3 to 5 nondialysis CKD (74% stage 3) in a parallel group, single-center superiority randomized controlled trial. Participants were randomized to either a 12-month individualized, multicomponent program or routine CKD care. The 3-component intervention—nutrition, psychological support, and exercise—was individualized based on findings from a comprehensive geriatric assessment (CGA). Outcome assessors and data analysts were blinded to group assignment. Loss to follow-up was low at 4.1%. The primary outcome—frailty reversion, defined as transition from Fried score ≥ 3 to < 3 at 1 year—was achieved in 30.6% versus 7.4% of controls (age-adjusted odds ratio: 5.22 [2.37–11.49]). Improvements were observed across the full range of CGA domains—physical performance, cognitive function, nutritional status, and activities of daily living. Initial frailty scoring occurred soon after hospitalization, a period when frailty scores may have been transiently elevated because of acute illness. The authors acknowledged this but note that separation between groups emerged predominantly at 12 months, potentially negating any effects attributable to acute changes. Generalizability of Findings From This Study Can these findings be generalized to populations elsewhere? The trial was conducted at a single tertiary hospital in Beijing, in a cohort with a mean estimated glomerular filtration rate of 41 ml/min per 1.73 m2. This cohort reflects relatively early CKD-associated clinical and metabolic derangement, where sarcopenia, nutritional depletion, and physical deconditioning remain modifiable targets. Generalization of these findings to more advanced stages of CKD may not be appropriate. A full CGA-based program of this kind requires a trained team, protected clinic time, and ongoing follow-up infrastructure, none of which are standard in most nephrology units. The more pragmatic path forward is likely to be brief frailty screening during routine CKD reviews, with referrals for a detailed CGA followed by individualized interventions for those who screen positive. Identifying the minimum effective combination of interventions and developing models adaptable to lower-resource settings is relevant to resource-stretched health systems. We need more studies across the CKD spectrum–trials, specifically in stages 4 and 5 CKD and in dialysis populations. Whether the same multicomponent model works in all contexts, and whether benefits persist despite increasing burden of illness (or dialysis), are all open questions. Because interventions in this trial were dictated by individual CGA findings rather than a standardized protocol, it is difficult to determine which components, or combinations, drive the observed benefit. Frailty Across the CKD Trajectory: Where This Evidence Fits The 2024 Kidney Disease: Improving Global Outcomes CKD guideline acknowledges frailty as a modifier of care targets in older adults.3 Specific frailty interventions have not been incorporated in guidelines yet because of a lack of evidence. This trial by Chang et al.2 provides randomized evidence in this area for stages 3 and 4 CKD. Where should frailty intervention sit in the CKD pathway? Older patients choosing comprehensive conservative care rather than dialysis are candidates for these measures as they are often multimorbid and frail. Findings from this study support the considerations of CGA followed by directed intervention in selected older patients with CKD, particularly where care goals prioritize function, independence, and quality of life. Another target group are the patients who experience precipitous functional decline in the months immediately after dialysis initiation.4 If functional reserve can be improved at CKD stages 3 and 4 as shown in this study, and maintained until stage 5, one can hypothesize that significant impacts of dialysis may be attenuated. This study only had a follow-up period of 1 year, so the question of persistent improvement cannot be answered here. However, these results should be seen as evidence of an opportunity to address frailty early in the CKD journey, before deficits become established. Finally, frailty at transplantation independently predicts graft loss, prolonged hospitalization, and mortality. Some transplant programs already incorporate frailty-directed prehabilitation measures. For example, the FRAILMar randomized trial in transplant candidates (baseline frailty in 40%) has reported improvements in exercise capacity and grip strength after structured prehabilitation. Effects on transplant outcomes are awaited.5 Patient-Centeredness of Outcomes Frailty reversal as a binary end point is valid and clinically interpretable, but it still reflects the clinician’s perspective. The Fried phenotype does not completely capture symptom burden, quality of life, social engagement, or subjective vitality. The Standardized Outcomes in Nephrology initiative has established that fatigue, ability to travel, and maintaining independence are high priority outcomes for patients with CKD.6 However, not all these outcomes were measured in this trial, and the extent to which frailty improvement translates into patient-relevant gains remains unknown. Future frailty intervention trials in CKD should incorporate validated patient-reported outcome measures — instruments such as the Patient-Reported Outcomes Measurement Information System fatigue scale, the EuroQol-5 Dimension, or the Kidney Disease Quality of Life instrument — to determine whether measured frailty improvement translates into meaningful changes in patients’ lives.7 Functional Improvements Versus Mortality Benefits Among the secondary outcomes in this study, death was treated as a competing event for hospitalization, avoiding the overestimation of hospitalization risk. Unplanned hospitalization (33.9% vs. 38.8%) and all-cause mortality (10.7% vs. 16.5%) were numerically lower in the intervention group, a trend that did not reach statistical significance. Since the trial was powered to detect differences in frailty reversion, these secondary findings are hypothesis-generating rather than definitive. The absence of effect on hospitalization and mortality in this trial should not be seen as discouraging. As suggested by the authors, the dominant causes of death in this cohort - infection (45.5%) and cardiovascular disease (42.4%) - are not targeted by the interventions in this study and may reflect decades of accumulated vascular damage. The broader literature also shows that in frail patients, the conversion of functional gains to reduction in mortality or hospitalization is less consistent.8 As an example, the REHAB-HF trial, a randomized study of tailored rehabilitation in decompensated heart failure, showed substantial physical performance gains at 3 months, but with no significant reduction in rehospitalisation.9 At a more fundamental level, the reversal of frailty should not be linked with the concept of survival in older adults because these are 2 very different goals. Interventions that only improve functional ability and cognitive reserve are still valuable, particularly where treatment goals are centered on optimizing quality of life within the constraints of age and illness. Chang et al.2 have demonstrated that frailty phenotype scores are modifiable in selected older patients with nondialysis CKD. The harder tasks remain—aligning what we measure with what patients actually value, and determining which interventions are the most effective. The urgency of answering these questions grows with the increasing numbers of older, frailer patients presenting to nephrology clinics worldwide. Disclosure The author declared no competing interests. References